Ligand Pharmaceuticals's annual revenues are $100-$500 million (see exact revenue data) and has 10-100 employees. It is classified as operating in the Scientific Research & Development Services industry.
Note: Ligand Pharmaceuticals's revenues are gauged from an analysis of company filings.
Ligand Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
January 25, 2016
Complete list of funding rounds and total amounts in the Company Report
Trademark applications show the products and services that Ligand Pharmaceuticals is developing and marketing.
Ligand Pharmaceuticals's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
LTP TECHNOLOGY Pharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations
LTP Pharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations
OMNIDAB Laboratory chemicals, namely, antibodies for use in scientific and medical research
Determine whether Ligand Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Ligand Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Ligand Pharmaceuticals's Largest Competitors
A competitive analysis shows these companies are in the same general field as Ligand Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Ligand Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Ligand Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.